Gilead leans on data, focus to launch filgotinib in crowded RA by Carly Helfand Tuesday, January 21, 2020 To set its rheumatoid arthritis candidate filgotinib apart from numerous rivals, Gilead has three priorities in mind for the launch.
Gilead's ready to spend big on Descovy, filgotinib launches: CEO by Carly Helfand Thursday, October 24, 2019 If Gilead’s investors are worried the company’s new leadership team won’t pony up to support key launches, they don’t need to be, its CEO says.
AbbVie's Rinvoq label portends safety warnings for future JAKs by Carly Helfand Monday, August 19, 2019 JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.
Lilly's baricitinib stunner helps Pfizer—and AbbVie, too by Tracy Staton Monday, April 17, 2017 Pfizer's Xeljanz is an obvious beneficiary of Eli Lilly's surprise Olumiant (baricitinib) rejection at the FDA. But AbbVie and Gilead could gain, too.
